FDA Needs To Track Actions Built On Supplement AERs – GAO Report
This article was originally published in The Tan Sheet
Executive Summary
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.